Previous close | 0.6789 |
Open | 0.6896 |
Bid | 0.6945 x 600 |
Ask | 0.7018 x 600 |
Day's range | 0.6735 - 0.7070 |
52-week range | 0.5200 - 1.5400 |
Volume | |
Avg. volume | 4,107,124 |
Market cap | 158.697M |
Beta (5Y monthly) | 0.65 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.5200 |
Earnings date | 01 Aug 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 09 Nov 2012 |
1y target est | 5.25 |
Key Insights Significant control over Vaxart by retail investors implies that the general public has more power to...
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and norovirus programs — SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today provided business and cash runway updates as the Company continues to advance its oral pill vaccine platform. Vaxart anticipates that net proceeds
Vaxart, Inc. (NASDAQ:VXRT) shares traded higher in the premarket session on Friday, up more than 23% at one point. Vaxart’s average session volume was about 1.6 million. Friday premarket’s session volume had exceeded four million at the time of writing. Yesterday, Vaxart obtained a project award worth $453 million through the Rapid Response Partnership Vehicle, supported by the Biomedical Advanced Research and Development Authority under the Administration for Strategic Preparedness and Response